Border to Coast Pensions Partnership Ltd Acquires Shares of 215,755 Zoetis Inc. $ZTS

Key Points

• Border to Coast Pensions Partnership Ltd has acquired 215,755 shares of Zoetis Inc., amounting to a value of approximately $33.6 million during the second quarter.
• Zoetis reported earnings of $1.76 per share for the last quarter, exceeding estimates, and projected an FY 2025 guidance between $6.300 and $6.400 EPS.
• Institutional investors own about 92.80% of Zoetis stock, indicating strong institutional support, with several firms increasing their positions in recent quarters.

Border to Coast Pensions Partnership Ltd purchased a new stake in Zoetis Inc. (NYSE:ZTS - Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 215,755 shares of the company's stock, valued at approximately $33,647,000.

Several other hedge funds also recently made changes to their positions in the business. Nuveen LLC bought a new stake in shares of Zoetis during the first quarter worth about $616,375,000. Sarasin & Partners LLP purchased a new position in shares of Zoetis during the first quarter worth about $339,111,000. Mackenzie Financial Corp lifted its position in Zoetis by 4,158.3% in the first quarter. Mackenzie Financial Corp now owns 1,824,967 shares of the company's stock valued at $300,481,000 after purchasing an additional 1,782,110 shares during the last quarter. GAMMA Investing LLC raised its holdings in shares of Zoetis by 14,731.3% during the first quarter. GAMMA Investing LLC now owns 1,759,285 shares of the company's stock valued at $289,666,000 after acquiring an additional 1,747,423 shares in the last quarter. Finally, Polen Capital Management LLC grew its stake in shares of Zoetis by 17.6% in the first quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company's stock worth $1,448,401,000 after acquiring an additional 1,313,653 shares during the last quarter. 92.80% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the company. Leerink Partners downgraded Zoetis from an "outperform" rating to a "market perform" rating and decreased their target price for the company from $180.00 to $155.00 in a research note on Thursday, July 17th. Leerink Partnrs lowered Zoetis from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 17th. Piper Sandler upped their target price on Zoetis from $210.00 to $215.00 and gave the company an "overweight" rating in a research note on Monday, August 11th. Stifel Nicolaus cut Zoetis from a "buy" rating to a "hold" rating and dropped their target price for the stock from $165.00 to $160.00 in a report on Wednesday, June 18th. Finally, Argus reissued a "buy" rating and issued a $190.00 price target on shares of Zoetis in a research note on Tuesday, September 9th. Five research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $200.88.

Zoetis Stock Down 0.9%

ZTS traded down $1.28 on Friday, reaching $145.82. The company's stock had a trading volume of 4,455,824 shares, compared to its average volume of 2,375,084. Zoetis Inc. has a 1 year low of $139.70 and a 1 year high of $197.51. The stock has a market cap of $64.63 billion, a price-to-earnings ratio of 25.10, a price-to-earnings-growth ratio of 2.34 and a beta of 0.88. The business's 50 day moving average is $151.25 and its 200 day moving average is $156.45. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04.

Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.62 by $0.14. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The business had revenue of $2.46 billion during the quarter, compared to analyst estimates of $2.41 billion. During the same period last year, the company earned $1.56 earnings per share. Zoetis's quarterly revenue was up 4.2% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, research analysts forecast that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.